Related references
Note: Only part of the references are listed.Catechols in post-mortem brain of patients with Parkinson disease
D. S. Goldstein et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease
Gessica Sala et al.
JOURNAL OF NEURAL TRANSMISSION (2010)
In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133
Nobuyuki Okamura et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Products of Oxidative Stress Inhibit Aldehyde Oxidation and Reduction Pathways in Dopamine Catabolism Yielding Elevated Levels of a Reactive Intermediate
Yunden Jinsmaa et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Cardiac sympathetic neuroimaging: summary of the First International Symposium
David S. Goldstein et al.
CLINICAL AUTONOMIC RESEARCH (2009)
Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity
Tonya N. Taylor et al.
JOURNAL OF NEUROSCIENCE (2009)
Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons
Eugene V. Mosharov et al.
NEURON (2009)
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease
Dennis W. Dickson et al.
ACTA NEUROPATHOLOGICA (2008)
Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells
Masahiko Watabe et al.
MOLECULAR PHARMACOLOGY (2008)
Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism
Yan Sai et al.
TOXICOLOGY IN VITRO (2008)
Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
William J. Burke et al.
ACTA NEUROPATHOLOGICA (2008)
Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells
Jun Tang Guo et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2008)
Dopamine transporter relation to dopamine turnover in Parkinson's disease:: A positron emission tomography study
Vesna Sossi et al.
ANNALS OF NEUROLOGY (2007)
Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate
Jennifer N. Rees et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2007)
Cardiac sympathetic denervation preceding motor signs in Parkinson disease
David S. Goldstein et al.
CLINICAL AUTONOMIC RESEARCH (2007)
α-synuclein overexpression increases cytosolic catecholamine concentration
Eugene V. Mosharov et al.
JOURNAL OF NEUROSCIENCE (2006)
Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry
Trent J. Volz et al.
JOURNAL OF NEUROSCIENCE METHODS (2006)
Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension - Independence from levodopa treatment
DS Goldstein et al.
HYPERTENSION (2005)
Profound cardiac sympathetic denervation occurs in Parkinson disease
T Amino et al.
BRAIN PATHOLOGY (2005)
Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells
HQ Liu et al.
ACTA PHARMACOLOGICA SINICA (2005)
Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease
M Sun et al.
HUMAN GENE THERAPY (2004)
Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress:: role of ferrous and ferric ions
A Hermida-Ameijeiras et al.
NEUROCHEMISTRY INTERNATIONAL (2004)
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases
WJ Burke et al.
NEUROTOXICOLOGY (2004)
Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension
DS Goldstein et al.
NEUROLOGY (2003)
Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy
S Orimo et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism
MJ Volles et al.
BIOCHEMISTRY (2002)
Increase in dopamine turnover occurs early in Parkinson's disease:: Evidence from a new modeling approach to PET 18F-fluorodopa data
V Sossi et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2002)
Kinetic model for the fate of 6-[F-18]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function
DS Goldstein et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2002)
Accumulation of alpha-synuclein in autonomic nem es in pure autonomic failure
H Kaufmann et al.
NEUROLOGY (2001)
Noninvasive detection of sympathetic neurocirculatory failure
DS Goldstein et al.
CLINICAL AUTONOMIC RESEARCH (2000)